نتایج جستجو برای: 177lu psma

تعداد نتایج: 2383  

2015
Samaneh Zolghadri Hassan Yousefnia Amir Reza Jalilian Yousef Fazaeli

Due to interesting therapeutic properties of 177Lu and tumor avidity of tetraphenyl porphyrins (TPPs), 177Lu-tetraphenyl porphyrin was developed as a possible therapeutic compound. 177Lu of 2.6-3 GBq/mg specific activity was obtained by irradiation of natural Lu2O3 sample with thermal neutron flux of 4 × 1013 n.cm-2.s-1. Tetraphenyl porphyrin was synthetized and labeled with 177Lu. Radiochemica...

2014
Johnnie J. Orozco Ethan R. Balkin Ted A. Gooley Aimee Kenoyer Donald K. Hamlin D. Scott Wilbur Darrell R. Fisher Mark D. Hylarides Mazyar Shadman Damian J. Green Ajay K. Gopal Oliver W. Press John M. Pagel

Radioimmunotherapy (RIT) for treatment of hematologic malignancies has primarily employed monoclonal antibodies (Ab) labeled with 131I or 90Y which have limitations, and alternative radionuclides are needed to facilitate wider adoption of RIT. We therefore compared the relative therapeutic efficacy and toxicity of anti-CD45 RIT employing 90Y and 177Lu in a syngeneic, disseminated murine myeloid...

Journal: :Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2008
Paulette Mhawech-Fauceglia Dominic J Smiraglia Wiam Bshara Christopher Andrews Juerg Schwaller Stacey South Donald Higgs Shashikant Lele Francois Herrmann Kunle Odunsi

The aim of this study was to determine the role of prostate-specific membrane antigen (PSMA) as a prognostic marker in endometrial adenocarcinoma (EAC) and to explore whether its down-regulation could be due to epigenetic mechanism. First, we examined the expression and the prognostic value of PSMA by semiquantitative reverse transcription-PCR and immunohistochemistry in EAC tissue samples. Sec...

2015
Margret Schottelius Martina Wirtz Matthias Eiber Tobias Maurer Hans-Jürgen Wester

BACKGROUND The relevance of prostate-specific membrane antigen (PSMA) targeting in the clinical management of prostate cancer (PCa) is continually increasing, entailing the development of PSMA-targeted molecular probes. Recently, a first PSMA-targeted theranostic concept has been successfully implemented by [(68)Ga/(177)Lu]PSMA-I&T. To further exploit the excellent PSMA-targeting characteristic...

2012
Maria Larsson Peter Bernhardt Johanna B Svensson Bo Wängberg Håkan Ahlman Eva Forssell-Aronsson

UNLABELLED BACKGROUND Lu-[DOTA0, Tyr3]-octreotate (177Lu-octreotate) is used to treat neuroendocrine tumors with high somatostatin-receptor expression. 177Lu-octreotate is mainly excreted via the kidneys, but to some extent, accumulates in the kidney cortex due to, e.g., tubular reabsorption. Renal toxicity is one of the main limiting factors in 177Lu-octreotate treatment. Further knowledge ...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2003
Roland Schroers Lei Shen Lisa Rollins Zhen Xiao Grete Sonderstrup Kevin Slawin Xue F Huang Si-Yi Chen

An effective tumor vaccine may be required to induce both CTLs and T-helper (Th) responses against tumor-associated antigens. CD4+ Th cells that recognize MHC class II-restricted epitopes play a central role in the initiation and maintenance of antitumor immune responses. Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer and thus is a potential target for prostate...

Journal: :European Journal of Nuclear Medicine and Molecular Imaging 2020

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید